Clonal Evolution and Therapy Related Selection Of TP53 Mutations In Chronic Lymphocytic Leukemia Patients
Plevova K, Malcikova J, Trbusek M et al.
Key Points:
TP53 mutations (mut-TP53) recognized as therapy related event in approximately one fifth of treated CLL patients and associated with higher disease aggressiveness and inferior clinical outcome.
Authors analyzed clonal evolution of CLL cells from patients who acquired new TP53 mutation after therapy.
Authors identified 38 CLL patients with intact TP53 gene before therapy but with newly acquired mut-TP53 during disease relapse.
Implications:
Selection of TP53 defects during CLL relapse seems to be accompanied by accumulation of specific copy number alterations(CNA), mainly deletions.
These CNAs may be consequence of genomic instability associated with TP53 defects.
View the original abstract on the ASH website.
